X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NMPA approved an bacterial DNA synthesis inhibitor antibiotic, metronidazole gel for the treatment of papulopustular rosacea, which uses Aptar Pharma’s Mezzo+ CS Airless dispensing solution for dermal drug delivery.
Lead Product(s): Metronidazole
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: TFF Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 03, 2022
Details:
Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (mannitol).
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Pharmaxis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 04, 2022
Details:
The agreement includes an investment by Opiant and a commitment by Aptar to install and maintain equipment in support of increased future production of its Unidose device to meet the potential commercial demand for OPNT003, nasal nalmefene.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2022
Details:
As per agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device & further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.
Lead Product(s): Mannitol API
Therapeutic Area: Genetic Disease Product Name: Bronchitol
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pharmaxis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 17, 2021
Details:
Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device. OPNT003 is a nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.
Lead Product(s): Nalmefene Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
